Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01888120 · ClinicalTrials.gov registry record
Patient Registry of Intrathecal Ziconotide Management(PRIZM)
A clinical trial, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- 93
- Enrollment target
NCT01888120: Completed study, sponsored by Jazz Pharmaceuticals.
NCT01888120 is a clinical trial that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01888120 has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- 93 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the effectiveness, long-term safety, tolerability, satisfaction with treatment, and health-related quality of life (HRQoL) associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.
Interventions
- DRUG Ziconotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-03 |
What the finished NCT01888120 record still lists
NCT01888120 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ziconotide is the first listed.
NCT01888120 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01888120 about?
NCT01888120 is a clinical study titled "Patient Registry of Intrathecal Ziconotide Management(PRIZM)". The objectives of this study are to evaluate the effectiveness, long-term safety, tolerability, satisfaction with treatment, and health-related quality of life (HRQoL) associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.
What is the current status of trial NCT01888120?
This trial is currently completed. The enrollment target is 93 participants. The study started on 2013-07. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01888120?
The interventions under investigation include: Ziconotide (DRUG).
Who is sponsoring clinical trial NCT01888120?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia